1,2-Diiminoperylene-3-sulfonyl chloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 菲及其衍生物
• 英文名称: 1,2-Diiminoperylene-3-sulfonyl chloride
• 英文别名: 1,2-diiminoperylene-3-sulfonyl chloride
• 化学式: C₂₀H₁₁ClN₂O₂S
• 分子量: 378.8
• InChiKey: HCPLVRXGRHWFQA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  26
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  90.2
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Biological substance detection method
  申请人：Konica Minolta, Inc.

  公开号：EP2757378A2

  公开（公告）日：2014-07-23

  The present invention provides a biological substance detection method for specifically detecting a biological substance from a pathological specimen, by which method, when immunostaining using a fluorescent label and staining for morphological observation using a staining agent for morphological observation are simultaneously performed, the results of fluorescence observation and immunostaining can be assessed properly even if the fluorescent label and/or the staining agent is/are deteriorated by irradiation with an excitation light. The biological substance detection method according to the present invention is characterized in that the brightness retention rate of an immunostained part is in a range of 80% to 120% in relation to the brightness retention rate of a part stained for morphological observation when the fluorescent label used for the immunostaining is observed.

  本发明提供了一种从病理标本中特异性检测生物物质的生物物质检测方法，通过该方法，当使用荧光标签进行免疫染色和使用形态观察用染色剂进行形态观察染色同时进行时，即使荧光标签和/或染色剂因激发光照射而变质，也能正确评估荧光观察和免疫染色的结果。根据本发明的生物物质检测方法的特点是，在观察用于免疫染色的荧光标签时，免疫染色部分的亮度保持率与用于形态观察的染色部分的亮度保持率相比在 80% 至 120% 的范围内。
• METHOD FOR DETECTING BIOLOGICAL MATERIAL
  申请人：Konica Minolta, Inc.

  公开号：EP2833140A1

  公开（公告）日：2015-02-04

  The present invention provides a staining method in which the fluorescent staining properties in a fluorescently-immunostained specimen are not reduced even when an oil-based mounting medium is used. The present invention also provides a method of preventing deterioration of a fluorescent label caused by irradiation with excitation light and improving the light resistance in a fluorescently-immunostained specimen obtained by the staining method. The biological substance detection method according to the present invention is a biological substance detection method for specifically detecting a biological substance from a pathological specimen, which comprises the steps of: immunostaining the specimen with a fluorescent label; immobilizing the thus stained specimen; and mounting the thus immobilized specimen using a mounting medium comprising an organic solvent not freely miscible with water. In the biological substance detection method, the above-described mounting medium further comprises a discoloration inhibitor.

  本发明提供了一种染色方法，在这种方法中，即使使用油基装载介质，也不会降低荧光免疫染色标本的荧光染色特性。本发明还提供了一种方法，可防止荧光标签因激发光照射而变质，并提高通过染色方法获得的荧光免疫染色标本的耐光性。根据本发明的生物物质检测方法是一种从病理标本中特异性检测生物物质的生物物质检测方法，它包括以下步骤：用荧光标签对标本进行免疫染色；将这样染色的标本固定；以及使用由与水不能自由混溶的有机溶剂组成的装载介质装载这样固定的标本。在生物物质检测方法中，上述安装介质还包括变色抑制剂。
• DRUG EVALUATION METHOD
  申请人：Konica Minolta, Inc.

  公开号：EP3715844A1

  公开（公告）日：2020-09-30

  The present invention relates to a method for evaluating a drug that is involved in angiogenesis. The method includes a drug administration step (A) in which the drug that is involved in angiogenesis is administered to a subject that has a lesion. The method also involves: performing an imaging step (1) in which radiography is performed on the subject after the blood vessels thereof have been made to contain metal nanoparticles or an imaging step (2) in which fluorescence staining and fluorescence imaging are performed using a dimeric protein; and evaluating the drug using an image acquired in imaging step (1) or (2).

  本发明涉及一种评估参与血管生成的药物的方法。该方法包括给药步骤（A），在该步骤中，向有病变的受试者给药参与血管生成的药物。该方法还包括：执行成像步骤 (1)，在其血管中含有金属纳米颗粒后对受试者进行射线照相，或执行成像步骤 (2)，使用二聚体蛋白进行荧光染色和荧光成像；以及使用成像步骤 (1) 或 (2) 中获取的图像评估药物。
• BIOLOGICAL SUBSTANCE DETECTION METHOD
  申请人：Konica Minolta, Inc.

  公开号：EP2755019B1

  公开（公告）日：2018-01-03
• Method for detecting biological material
  申请人：Konica Minolta, Inc.

  公开号：EP2833140B1

  公开（公告）日：2018-05-09